Redhill Biopharma Ltd
NASDAQ:RDHL
Redhill Biopharma Ltd
Revenue
Redhill Biopharma Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Redhill Biopharma Ltd
NASDAQ:RDHL
|
Revenue
$6.5m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Revenue
$15.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-2%
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Revenue
$610.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
I
|
InterCure Ltd
TASE:INCR
|
Revenue
₪414.8m
|
CAGR 3-Years
164%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
48%
|
Mediwound Ltd
NASDAQ:MDWD
|
Revenue
$18.7m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Revenue
₪315.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
1%
|
See Also
What is Redhill Biopharma Ltd's Revenue?
Revenue
6.5m
USD
Based on the financial report for Dec 31, 2023, Redhill Biopharma Ltd's Revenue amounts to 6.5m USD.
What is Redhill Biopharma Ltd's Revenue growth rate?
Revenue CAGR 5Y
-5%
Over the last year, the Revenue growth was -89%. The average annual Revenue growth rates for Redhill Biopharma Ltd have been -53% over the past three years , -5% over the past five years .